Federal Register Notice: FDA is making available a guidance for industry entitled Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation. It provides recommendations to sponsors of NDAs and ANDAs on what criteria should be met when evaluating and labeling tablets that have been scored, a feature that facilitates tablet splitting. To download this guidance, click here. To view this notice, click here.
